nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—colon cancer—Dexamethasone—multiple sclerosis	0.242	0.366	CpDpCtD
Aprepitant—colon cancer—Betamethasone—multiple sclerosis	0.242	0.366	CpDpCtD
Aprepitant—breast cancer—Betamethasone—multiple sclerosis	0.0889	0.134	CpDpCtD
Aprepitant—breast cancer—Dexamethasone—multiple sclerosis	0.0889	0.134	CpDpCtD
Aprepitant—CYP3A4—Fingolimod—multiple sclerosis	0.0176	0.124	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0147	0.103	CbGbCtD
Aprepitant—CYP3A7—Dexamethasone—multiple sclerosis	0.0147	0.103	CbGbCtD
Aprepitant—CYP2C19—Prednisone—multiple sclerosis	0.0142	0.0998	CbGbCtD
Aprepitant—CYP3A4—Methylprednisolone—multiple sclerosis	0.0114	0.0796	CbGbCtD
Aprepitant—CYP3A5—Dexamethasone—multiple sclerosis	0.011	0.0772	CbGbCtD
Aprepitant—TACR1—trigeminal nerve—multiple sclerosis	0.00953	0.283	CbGeAlD
Aprepitant—CYP2C19—Dexamethasone—multiple sclerosis	0.00888	0.0623	CbGbCtD
Aprepitant—CYP3A4—Triamcinolone—multiple sclerosis	0.00861	0.0603	CbGbCtD
Aprepitant—CYP3A4—Mitoxantrone—multiple sclerosis	0.00828	0.0581	CbGbCtD
Aprepitant—CYP2C9—Dexamethasone—multiple sclerosis	0.00739	0.0518	CbGbCtD
Aprepitant—CYP3A4—Betamethasone—multiple sclerosis	0.00738	0.0518	CbGbCtD
Aprepitant—CYP3A4—Prednisolone—multiple sclerosis	0.00729	0.0511	CbGbCtD
Aprepitant—CYP3A4—Prednisone—multiple sclerosis	0.00688	0.0482	CbGbCtD
Aprepitant—TACR1—peripheral nervous system—multiple sclerosis	0.00446	0.133	CbGeAlD
Aprepitant—CYP3A4—Dexamethasone—multiple sclerosis	0.0043	0.0301	CbGbCtD
Aprepitant—TACR3—brainstem—multiple sclerosis	0.00386	0.115	CbGeAlD
Aprepitant—TACR1—nerve—multiple sclerosis	0.00348	0.103	CbGeAlD
Aprepitant—TACR3—nervous system—multiple sclerosis	0.00202	0.0601	CbGeAlD
Aprepitant—TACR3—central nervous system—multiple sclerosis	0.00195	0.0578	CbGeAlD
Aprepitant—TACR3—cerebellum—multiple sclerosis	0.0019	0.0565	CbGeAlD
Aprepitant—TACR3—brain—multiple sclerosis	0.00154	0.0459	CbGeAlD
Aprepitant—TACR1—brainstem—multiple sclerosis	0.00149	0.0444	CbGeAlD
Aprepitant—TACR1—spinal cord—multiple sclerosis	0.000929	0.0276	CbGeAlD
Aprepitant—TACR1—nervous system—multiple sclerosis	0.000783	0.0233	CbGeAlD
Aprepitant—TACR1—central nervous system—multiple sclerosis	0.000754	0.0224	CbGeAlD
Aprepitant—TACR1—brain—multiple sclerosis	0.000598	0.0178	CbGeAlD
Aprepitant—CYP3A4—nervous system—multiple sclerosis	0.000177	0.00525	CbGeAlD
Aprepitant—CYP3A4—central nervous system—multiple sclerosis	0.00017	0.00506	CbGeAlD
Aprepitant—TACR1—Peptide ligand-binding receptors—CCL2—multiple sclerosis	9.51e-05	0.0018	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCR1—multiple sclerosis	9.5e-05	0.00179	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CXCL13—multiple sclerosis	9.5e-05	0.00179	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CXCL10—multiple sclerosis	9.48e-05	0.00179	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—GPR65—multiple sclerosis	9.45e-05	0.00178	CbGpPWpGaD
Aprepitant—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	9.39e-05	0.00177	CbGpPWpGaD
Aprepitant—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	9.39e-05	0.00177	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	9.26e-05	0.00175	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	9.26e-05	0.00175	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	9.26e-05	0.00175	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	9.14e-05	0.00173	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CNR1—multiple sclerosis	9.1e-05	0.00172	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—RGS1—multiple sclerosis	9.05e-05	0.00171	CbGpPWpGaD
Aprepitant—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.77e-05	0.00166	CbGpPWpGaD
Aprepitant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	8.75e-05	0.00165	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CCR1—multiple sclerosis	8.64e-05	0.00163	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCL13—multiple sclerosis	8.64e-05	0.00163	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CXCL10—multiple sclerosis	8.61e-05	0.00163	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—GPR65—multiple sclerosis	8.58e-05	0.00162	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	8.56e-05	0.00162	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	8.56e-05	0.00162	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	8.44e-05	0.00159	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	8.44e-05	0.00159	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	8.44e-05	0.00159	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	8.34e-05	0.00157	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—LINGO1—multiple sclerosis	8.3e-05	0.00157	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—MYC—multiple sclerosis	8.22e-05	0.00155	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—TGFB1—multiple sclerosis	8.2e-05	0.00155	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CXCL10—multiple sclerosis	8.19e-05	0.00155	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CCL5—multiple sclerosis	8.16e-05	0.00154	CbGpPWpGaD
Aprepitant—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	8.08e-05	0.00153	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—MAPK1—multiple sclerosis	8.05e-05	0.00152	CbGpPWpGaD
Aprepitant—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	7.96e-05	0.0015	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CCR1—multiple sclerosis	7.85e-05	0.00148	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCL13—multiple sclerosis	7.85e-05	0.00148	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	7.83e-05	0.00148	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	7.82e-05	0.00148	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—TNF—multiple sclerosis	7.66e-05	0.00145	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CCL5—multiple sclerosis	7.41e-05	0.0014	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CCR5—multiple sclerosis	7.35e-05	0.00139	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	7.31e-05	0.00138	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	7.31e-05	0.00138	CbGpPWpGaD
Aprepitant—Alopecia—Prednisone—multiple sclerosis	7.3e-05	0.000674	CcSEcCtD
Aprepitant—Shock—Methylprednisolone—multiple sclerosis	7.29e-05	0.000673	CcSEcCtD
Aprepitant—Nervous system disorder—Methylprednisolone—multiple sclerosis	7.27e-05	0.000671	CcSEcCtD
Aprepitant—Loss of consciousness—Betamethasone—multiple sclerosis	7.26e-05	0.00067	CcSEcCtD
Aprepitant—Loss of consciousness—Dexamethasone—multiple sclerosis	7.26e-05	0.00067	CcSEcCtD
Aprepitant—Hypersensitivity—Mitoxantrone—multiple sclerosis	7.25e-05	0.00067	CcSEcCtD
Aprepitant—Paraesthesia—Prednisolone—multiple sclerosis	7.25e-05	0.000669	CcSEcCtD
Aprepitant—Tachycardia—Triamcinolone—multiple sclerosis	7.25e-05	0.000669	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—IL2RA—multiple sclerosis	7.24e-05	0.00137	CbGpPWpGaD
Aprepitant—Mental disorder—Prednisone—multiple sclerosis	7.24e-05	0.000668	CcSEcCtD
Aprepitant—Nausea—Azathioprine—multiple sclerosis	7.23e-05	0.000668	CcSEcCtD
Aprepitant—Tachycardia—Methylprednisolone—multiple sclerosis	7.23e-05	0.000668	CcSEcCtD
Aprepitant—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	7.21e-05	0.00136	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	7.21e-05	0.00136	CbGpPWpGaD
Aprepitant—Skin disorder—Methylprednisolone—multiple sclerosis	7.2e-05	0.000664	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—TAGAP—multiple sclerosis	7.2e-05	0.00136	CbGpPWpGaD
Aprepitant—Malnutrition—Prednisone—multiple sclerosis	7.19e-05	0.000664	CcSEcCtD
Aprepitant—Erythema—Prednisone—multiple sclerosis	7.19e-05	0.000664	CcSEcCtD
Aprepitant—Hyperhidrosis—Triamcinolone—multiple sclerosis	7.18e-05	0.000663	CcSEcCtD
Aprepitant—Hyperhidrosis—Methylprednisolone—multiple sclerosis	7.16e-05	0.000661	CcSEcCtD
Aprepitant—Convulsion—Betamethasone—multiple sclerosis	7.15e-05	0.00066	CcSEcCtD
Aprepitant—Convulsion—Dexamethasone—multiple sclerosis	7.15e-05	0.00066	CcSEcCtD
Aprepitant—Hypertension—Dexamethasone—multiple sclerosis	7.13e-05	0.000658	CcSEcCtD
Aprepitant—Hypertension—Betamethasone—multiple sclerosis	7.13e-05	0.000658	CcSEcCtD
Aprepitant—CYP3A7—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.11e-05	0.00134	CbGpPWpGaD
Aprepitant—Asthenia—Mitoxantrone—multiple sclerosis	7.06e-05	0.000652	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—CCL5—multiple sclerosis	7.05e-05	0.00133	CbGpPWpGaD
Aprepitant—Myalgia—Dexamethasone—multiple sclerosis	7.03e-05	0.000649	CcSEcCtD
Aprepitant—Myalgia—Betamethasone—multiple sclerosis	7.03e-05	0.000649	CcSEcCtD
Aprepitant—Anxiety—Dexamethasone—multiple sclerosis	7.01e-05	0.000647	CcSEcCtD
Aprepitant—Anxiety—Betamethasone—multiple sclerosis	7.01e-05	0.000647	CcSEcCtD
Aprepitant—Discomfort—Betamethasone—multiple sclerosis	6.95e-05	0.000641	CcSEcCtD
Aprepitant—Discomfort—Dexamethasone—multiple sclerosis	6.95e-05	0.000641	CcSEcCtD
Aprepitant—Hypotension—Methylprednisolone—multiple sclerosis	6.92e-05	0.000639	CcSEcCtD
Aprepitant—Pain—Prednisolone—multiple sclerosis	6.91e-05	0.000638	CcSEcCtD
Aprepitant—Pharyngitis—Methotrexate—multiple sclerosis	6.85e-05	0.000633	CcSEcCtD
Aprepitant—Urinary tract disorder—Methotrexate—multiple sclerosis	6.82e-05	0.000629	CcSEcCtD
Aprepitant—Urethral disorder—Methotrexate—multiple sclerosis	6.77e-05	0.000625	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	6.77e-05	0.000625	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CCL3—multiple sclerosis	6.77e-05	0.00128	CbGpPWpGaD
Aprepitant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	6.76e-05	0.00128	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	6.75e-05	0.000623	CcSEcCtD
Aprepitant—Oedema—Dexamethasone—multiple sclerosis	6.74e-05	0.000622	CcSEcCtD
Aprepitant—Anaphylactic shock—Dexamethasone—multiple sclerosis	6.74e-05	0.000622	CcSEcCtD
Aprepitant—Anaphylactic shock—Betamethasone—multiple sclerosis	6.74e-05	0.000622	CcSEcCtD
Aprepitant—Oedema—Betamethasone—multiple sclerosis	6.74e-05	0.000622	CcSEcCtD
Aprepitant—Diarrhoea—Mitoxantrone—multiple sclerosis	6.74e-05	0.000622	CcSEcCtD
Aprepitant—Insomnia—Triamcinolone—multiple sclerosis	6.72e-05	0.00062	CcSEcCtD
Aprepitant—Insomnia—Methylprednisolone—multiple sclerosis	6.7e-05	0.000619	CcSEcCtD
Aprepitant—Infection—Betamethasone—multiple sclerosis	6.7e-05	0.000618	CcSEcCtD
Aprepitant—Infection—Dexamethasone—multiple sclerosis	6.7e-05	0.000618	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—CCR5—multiple sclerosis	6.67e-05	0.00126	CbGpPWpGaD
Aprepitant—Ill-defined disorder—Prednisone—multiple sclerosis	6.67e-05	0.000616	CcSEcCtD
Aprepitant—Paraesthesia—Triamcinolone—multiple sclerosis	6.67e-05	0.000616	CcSEcCtD
Aprepitant—Feeling abnormal—Prednisolone—multiple sclerosis	6.66e-05	0.000614	CcSEcCtD
Aprepitant—Paraesthesia—Methylprednisolone—multiple sclerosis	6.65e-05	0.000614	CcSEcCtD
Aprepitant—Anaemia—Prednisone—multiple sclerosis	6.65e-05	0.000614	CcSEcCtD
Aprepitant—Shock—Dexamethasone—multiple sclerosis	6.63e-05	0.000612	CcSEcCtD
Aprepitant—Shock—Betamethasone—multiple sclerosis	6.63e-05	0.000612	CcSEcCtD
Aprepitant—Dyspnoea—Triamcinolone—multiple sclerosis	6.62e-05	0.000611	CcSEcCtD
Aprepitant—Nervous system disorder—Betamethasone—multiple sclerosis	6.61e-05	0.00061	CcSEcCtD
Aprepitant—Nervous system disorder—Dexamethasone—multiple sclerosis	6.61e-05	0.00061	CcSEcCtD
Aprepitant—Thrombocytopenia—Betamethasone—multiple sclerosis	6.6e-05	0.000609	CcSEcCtD
Aprepitant—Thrombocytopenia—Dexamethasone—multiple sclerosis	6.6e-05	0.000609	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—IL2RA—multiple sclerosis	6.58e-05	0.00124	CbGpPWpGaD
Aprepitant—Tachycardia—Betamethasone—multiple sclerosis	6.58e-05	0.000607	CcSEcCtD
Aprepitant—Tachycardia—Dexamethasone—multiple sclerosis	6.58e-05	0.000607	CcSEcCtD
Aprepitant—Angioedema—Prednisone—multiple sclerosis	6.57e-05	0.000607	CcSEcCtD
Aprepitant—Dyspepsia—Triamcinolone—multiple sclerosis	6.54e-05	0.000604	CcSEcCtD
Aprepitant—Erythema multiforme—Methotrexate—multiple sclerosis	6.53e-05	0.000603	CcSEcCtD
Aprepitant—Dyspepsia—Methylprednisolone—multiple sclerosis	6.52e-05	0.000602	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	6.52e-05	0.00123	CbGpPWpGaD
Aprepitant—Hyperhidrosis—Betamethasone—multiple sclerosis	6.52e-05	0.000601	CcSEcCtD
Aprepitant—Hyperhidrosis—Dexamethasone—multiple sclerosis	6.52e-05	0.000601	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—PTGER4—multiple sclerosis	6.51e-05	0.00123	CbGpPWpGaD
Aprepitant—Malaise—Prednisone—multiple sclerosis	6.49e-05	0.000599	CcSEcCtD
Aprepitant—Eye disorder—Methotrexate—multiple sclerosis	6.45e-05	0.000596	CcSEcCtD
Aprepitant—Syncope—Prednisone—multiple sclerosis	6.45e-05	0.000595	CcSEcCtD
Aprepitant—Tinnitus—Methotrexate—multiple sclerosis	6.44e-05	0.000594	CcSEcCtD
Aprepitant—Anorexia—Betamethasone—multiple sclerosis	6.42e-05	0.000593	CcSEcCtD
Aprepitant—Anorexia—Dexamethasone—multiple sclerosis	6.42e-05	0.000593	CcSEcCtD
Aprepitant—Urticaria—Prednisolone—multiple sclerosis	6.42e-05	0.000592	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—PGR—multiple sclerosis	6.41e-05	0.00121	CbGpPWpGaD
Aprepitant—Cardiac disorder—Methotrexate—multiple sclerosis	6.41e-05	0.000591	CcSEcCtD
Aprepitant—Fatigue—Triamcinolone—multiple sclerosis	6.4e-05	0.000591	CcSEcCtD
Aprepitant—Fatigue—Methylprednisolone—multiple sclerosis	6.39e-05	0.00059	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	6.38e-05	0.0012	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CCR5—multiple sclerosis	6.35e-05	0.0012	CbGpPWpGaD
Aprepitant—Pain—Triamcinolone—multiple sclerosis	6.35e-05	0.000586	CcSEcCtD
Aprepitant—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.34e-05	0.0012	CbGpPWpGaD
Aprepitant—Loss of consciousness—Prednisone—multiple sclerosis	6.32e-05	0.000583	CcSEcCtD
Aprepitant—Hypotension—Betamethasone—multiple sclerosis	6.3e-05	0.000581	CcSEcCtD
Aprepitant—Hypotension—Dexamethasone—multiple sclerosis	6.3e-05	0.000581	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CXCR3—multiple sclerosis	6.29e-05	0.00119	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—S1PR1—multiple sclerosis	6.29e-05	0.00119	CbGpPWpGaD
Aprepitant—Angiopathy—Methotrexate—multiple sclerosis	6.26e-05	0.000578	CcSEcCtD
Aprepitant—Vomiting—Mitoxantrone—multiple sclerosis	6.26e-05	0.000578	CcSEcCtD
Aprepitant—Immune system disorder—Methotrexate—multiple sclerosis	6.24e-05	0.000576	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CD28—multiple sclerosis	6.23e-05	0.00118	CbGpPWpGaD
Aprepitant—Convulsion—Prednisone—multiple sclerosis	6.23e-05	0.000575	CcSEcCtD
Aprepitant—Mediastinal disorder—Methotrexate—multiple sclerosis	6.22e-05	0.000574	CcSEcCtD
Aprepitant—Hypertension—Prednisone—multiple sclerosis	6.21e-05	0.000573	CcSEcCtD
Aprepitant—Rash—Mitoxantrone—multiple sclerosis	6.21e-05	0.000573	CcSEcCtD
Aprepitant—Dermatitis—Mitoxantrone—multiple sclerosis	6.2e-05	0.000572	CcSEcCtD
Aprepitant—Chills—Methotrexate—multiple sclerosis	6.19e-05	0.000572	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—IL6—multiple sclerosis	6.18e-05	0.00117	CbGpPWpGaD
Aprepitant—Headache—Mitoxantrone—multiple sclerosis	6.17e-05	0.000569	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	6.14e-05	0.000567	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	6.14e-05	0.000567	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—TNF—multiple sclerosis	6.13e-05	0.00116	CbGpPWpGaD
Aprepitant—Arthralgia—Prednisone—multiple sclerosis	6.12e-05	0.000565	CcSEcCtD
Aprepitant—Myalgia—Prednisone—multiple sclerosis	6.12e-05	0.000565	CcSEcCtD
Aprepitant—Feeling abnormal—Triamcinolone—multiple sclerosis	6.12e-05	0.000565	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CCR2—multiple sclerosis	6.12e-05	0.00116	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—GPC5—multiple sclerosis	6.12e-05	0.00116	CbGpPWpGaD
Aprepitant—Feeling abnormal—Methylprednisolone—multiple sclerosis	6.11e-05	0.000564	CcSEcCtD
Aprepitant—Anxiety—Prednisone—multiple sclerosis	6.1e-05	0.000563	CcSEcCtD
Aprepitant—Alopecia—Methotrexate—multiple sclerosis	6.1e-05	0.000563	CcSEcCtD
Aprepitant—Insomnia—Betamethasone—multiple sclerosis	6.1e-05	0.000563	CcSEcCtD
Aprepitant—Insomnia—Dexamethasone—multiple sclerosis	6.1e-05	0.000563	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	6.08e-05	0.000561	CcSEcCtD
Aprepitant—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	6.06e-05	0.000559	CcSEcCtD
Aprepitant—Paraesthesia—Dexamethasone—multiple sclerosis	6.05e-05	0.000559	CcSEcCtD
Aprepitant—Paraesthesia—Betamethasone—multiple sclerosis	6.05e-05	0.000559	CcSEcCtD
Aprepitant—Discomfort—Prednisone—multiple sclerosis	6.05e-05	0.000558	CcSEcCtD
Aprepitant—Mental disorder—Methotrexate—multiple sclerosis	6.05e-05	0.000558	CcSEcCtD
Aprepitant—Malnutrition—Methotrexate—multiple sclerosis	6.01e-05	0.000555	CcSEcCtD
Aprepitant—Erythema—Methotrexate—multiple sclerosis	6.01e-05	0.000555	CcSEcCtD
Aprepitant—Hypersensitivity—Prednisolone—multiple sclerosis	5.95e-05	0.000549	CcSEcCtD
Aprepitant—Dyspepsia—Dexamethasone—multiple sclerosis	5.93e-05	0.000548	CcSEcCtD
Aprepitant—Dyspepsia—Betamethasone—multiple sclerosis	5.93e-05	0.000548	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—PTGER4—multiple sclerosis	5.93e-05	0.00112	CbGpPWpGaD
Aprepitant—Urticaria—Triamcinolone—multiple sclerosis	5.9e-05	0.000545	CcSEcCtD
Aprepitant—Urticaria—Methylprednisolone—multiple sclerosis	5.89e-05	0.000543	CcSEcCtD
Aprepitant—Dysgeusia—Methotrexate—multiple sclerosis	5.89e-05	0.000543	CcSEcCtD
Aprepitant—Body temperature increased—Triamcinolone—multiple sclerosis	5.87e-05	0.000542	CcSEcCtD
Aprepitant—Anaphylactic shock—Prednisone—multiple sclerosis	5.87e-05	0.000542	CcSEcCtD
Aprepitant—Oedema—Prednisone—multiple sclerosis	5.87e-05	0.000542	CcSEcCtD
Aprepitant—Abdominal pain—Methylprednisolone—multiple sclerosis	5.86e-05	0.000541	CcSEcCtD
Aprepitant—Decreased appetite—Betamethasone—multiple sclerosis	5.86e-05	0.000541	CcSEcCtD
Aprepitant—Decreased appetite—Dexamethasone—multiple sclerosis	5.86e-05	0.000541	CcSEcCtD
Aprepitant—Nausea—Mitoxantrone—multiple sclerosis	5.85e-05	0.00054	CcSEcCtD
Aprepitant—Infection—Prednisone—multiple sclerosis	5.83e-05	0.000538	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Betamethasone—multiple sclerosis	5.82e-05	0.000537	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	5.82e-05	0.000537	CcSEcCtD
Aprepitant—Back pain—Methotrexate—multiple sclerosis	5.81e-05	0.000537	CcSEcCtD
Aprepitant—Fatigue—Dexamethasone—multiple sclerosis	5.81e-05	0.000536	CcSEcCtD
Aprepitant—Fatigue—Betamethasone—multiple sclerosis	5.81e-05	0.000536	CcSEcCtD
Aprepitant—Shock—Prednisone—multiple sclerosis	5.77e-05	0.000533	CcSEcCtD
Aprepitant—Pain—Dexamethasone—multiple sclerosis	5.76e-05	0.000532	CcSEcCtD
Aprepitant—Pain—Betamethasone—multiple sclerosis	5.76e-05	0.000532	CcSEcCtD
Aprepitant—Nervous system disorder—Prednisone—multiple sclerosis	5.76e-05	0.000531	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—POMC—multiple sclerosis	5.74e-05	0.00108	CbGpPWpGaD
Aprepitant—Tachycardia—Prednisone—multiple sclerosis	5.73e-05	0.000529	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—CXCR3—multiple sclerosis	5.73e-05	0.00108	CbGpPWpGaD
Aprepitant—Skin disorder—Prednisone—multiple sclerosis	5.7e-05	0.000526	CcSEcCtD
Aprepitant—Hyperhidrosis—Prednisone—multiple sclerosis	5.67e-05	0.000524	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CNR1—multiple sclerosis	5.65e-05	0.00107	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	5.64e-05	0.00107	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	5.64e-05	0.00107	CbGpPWpGaD
Aprepitant—Anorexia—Prednisone—multiple sclerosis	5.59e-05	0.000516	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—CCL3—multiple sclerosis	5.59e-05	0.00106	CbGpPWpGaD
Aprepitant—Ill-defined disorder—Methotrexate—multiple sclerosis	5.58e-05	0.000515	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—CCR2—multiple sclerosis	5.57e-05	0.00105	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	5.57e-05	0.00105	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	5.57e-05	0.00105	CbGpPWpGaD
Aprepitant—Anaemia—Methotrexate—multiple sclerosis	5.55e-05	0.000513	CcSEcCtD
Aprepitant—Feeling abnormal—Betamethasone—multiple sclerosis	5.55e-05	0.000513	CcSEcCtD
Aprepitant—Feeling abnormal—Dexamethasone—multiple sclerosis	5.55e-05	0.000513	CcSEcCtD
Aprepitant—Gastrointestinal pain—Dexamethasone—multiple sclerosis	5.51e-05	0.000509	CcSEcCtD
Aprepitant—Gastrointestinal pain—Betamethasone—multiple sclerosis	5.51e-05	0.000509	CcSEcCtD
Aprepitant—Hypersensitivity—Triamcinolone—multiple sclerosis	5.47e-05	0.000505	CcSEcCtD
Aprepitant—Hypersensitivity—Methylprednisolone—multiple sclerosis	5.46e-05	0.000504	CcSEcCtD
Aprepitant—Malaise—Methotrexate—multiple sclerosis	5.42e-05	0.0005	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—PTGER4—multiple sclerosis	5.38e-05	0.00102	CbGpPWpGaD
Aprepitant—Urticaria—Betamethasone—multiple sclerosis	5.35e-05	0.000494	CcSEcCtD
Aprepitant—Urticaria—Dexamethasone—multiple sclerosis	5.35e-05	0.000494	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—RGS1—multiple sclerosis	5.35e-05	0.00101	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Prednisone—multiple sclerosis	5.35e-05	0.000494	CcSEcCtD
Aprepitant—Dizziness—Prednisolone—multiple sclerosis	5.34e-05	0.000493	CcSEcCtD
Aprepitant—Asthenia—Triamcinolone—multiple sclerosis	5.33e-05	0.000492	CcSEcCtD
Aprepitant—Abdominal pain—Dexamethasone—multiple sclerosis	5.33e-05	0.000492	CcSEcCtD
Aprepitant—Body temperature increased—Betamethasone—multiple sclerosis	5.33e-05	0.000492	CcSEcCtD
Aprepitant—Body temperature increased—Dexamethasone—multiple sclerosis	5.33e-05	0.000492	CcSEcCtD
Aprepitant—Abdominal pain—Betamethasone—multiple sclerosis	5.33e-05	0.000492	CcSEcCtD
Aprepitant—Asthenia—Methylprednisolone—multiple sclerosis	5.32e-05	0.000491	CcSEcCtD
Aprepitant—Insomnia—Prednisone—multiple sclerosis	5.31e-05	0.00049	CcSEcCtD
Aprepitant—Paraesthesia—Prednisone—multiple sclerosis	5.27e-05	0.000486	CcSEcCtD
Aprepitant—Pruritus—Triamcinolone—multiple sclerosis	5.25e-05	0.000485	CcSEcCtD
Aprepitant—Cough—Methotrexate—multiple sclerosis	5.24e-05	0.000484	CcSEcCtD
Aprepitant—Pruritus—Methylprednisolone—multiple sclerosis	5.24e-05	0.000484	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—POMC—multiple sclerosis	5.22e-05	0.000985	CbGpPWpGaD
Aprepitant—Convulsion—Methotrexate—multiple sclerosis	5.21e-05	0.000481	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—CXCR3—multiple sclerosis	5.2e-05	0.000982	CbGpPWpGaD
Aprepitant—Dyspepsia—Prednisone—multiple sclerosis	5.17e-05	0.000477	CcSEcCtD
Aprepitant—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.14e-05	0.000971	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CNR1—multiple sclerosis	5.14e-05	0.000971	CbGpPWpGaD
Aprepitant—Chest pain—Methotrexate—multiple sclerosis	5.12e-05	0.000472	CcSEcCtD
Aprepitant—Myalgia—Methotrexate—multiple sclerosis	5.12e-05	0.000472	CcSEcCtD
Aprepitant—Arthralgia—Methotrexate—multiple sclerosis	5.12e-05	0.000472	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—CCL2—multiple sclerosis	5.1e-05	0.000964	CbGpPWpGaD
Aprepitant—Decreased appetite—Prednisone—multiple sclerosis	5.1e-05	0.000471	CcSEcCtD
Aprepitant—Rash—Prednisolone—multiple sclerosis	5.09e-05	0.00047	CcSEcCtD
Aprepitant—Dermatitis—Prednisolone—multiple sclerosis	5.09e-05	0.00047	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CXCL10—multiple sclerosis	5.08e-05	0.00096	CbGpPWpGaD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	5.08e-05	0.000469	CcSEcCtD
Aprepitant—Diarrhoea—Methylprednisolone—multiple sclerosis	5.07e-05	0.000468	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—GPR65—multiple sclerosis	5.07e-05	0.000957	CbGpPWpGaD
Aprepitant—Fatigue—Prednisone—multiple sclerosis	5.06e-05	0.000467	CcSEcCtD
Aprepitant—Headache—Prednisolone—multiple sclerosis	5.06e-05	0.000467	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—CCR2—multiple sclerosis	5.06e-05	0.000955	CbGpPWpGaD
Aprepitant—Discomfort—Methotrexate—multiple sclerosis	5.06e-05	0.000467	CcSEcCtD
Aprepitant—Constipation—Prednisone—multiple sclerosis	5.02e-05	0.000463	CcSEcCtD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	4.98e-05	0.00094	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—POMC—multiple sclerosis	4.96e-05	0.000937	CbGpPWpGaD
Aprepitant—Confusional state—Methotrexate—multiple sclerosis	4.95e-05	0.000457	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL6—multiple sclerosis	4.94e-05	0.000934	CbGpPWpGaD
Aprepitant—Dizziness—Triamcinolone—multiple sclerosis	4.91e-05	0.000453	CcSEcCtD
Aprepitant—Anaphylactic shock—Methotrexate—multiple sclerosis	4.9e-05	0.000453	CcSEcCtD
Aprepitant—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.9e-05	0.000926	CbGpPWpGaD
Aprepitant—Dizziness—Methylprednisolone—multiple sclerosis	4.9e-05	0.000452	CcSEcCtD
Aprepitant—Infection—Methotrexate—multiple sclerosis	4.87e-05	0.00045	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—CCL2—multiple sclerosis	4.86e-05	0.000917	CbGpPWpGaD
Aprepitant—Feeling abnormal—Prednisone—multiple sclerosis	4.84e-05	0.000446	CcSEcCtD
Aprepitant—Asthenia—Betamethasone—multiple sclerosis	4.84e-05	0.000446	CcSEcCtD
Aprepitant—Asthenia—Dexamethasone—multiple sclerosis	4.84e-05	0.000446	CcSEcCtD
Aprepitant—Nervous system disorder—Methotrexate—multiple sclerosis	4.81e-05	0.000444	CcSEcCtD
Aprepitant—Thrombocytopenia—Methotrexate—multiple sclerosis	4.8e-05	0.000443	CcSEcCtD
Aprepitant—Gastrointestinal pain—Prednisone—multiple sclerosis	4.8e-05	0.000443	CcSEcCtD
Aprepitant—Nausea—Prednisolone—multiple sclerosis	4.8e-05	0.000443	CcSEcCtD
Aprepitant—Pruritus—Betamethasone—multiple sclerosis	4.77e-05	0.00044	CcSEcCtD
Aprepitant—Pruritus—Dexamethasone—multiple sclerosis	4.77e-05	0.00044	CcSEcCtD
Aprepitant—Skin disorder—Methotrexate—multiple sclerosis	4.76e-05	0.00044	CcSEcCtD
Aprepitant—Hyperhidrosis—Methotrexate—multiple sclerosis	4.74e-05	0.000438	CcSEcCtD
Aprepitant—Vomiting—Triamcinolone—multiple sclerosis	4.72e-05	0.000436	CcSEcCtD
Aprepitant—Vomiting—Methylprednisolone—multiple sclerosis	4.71e-05	0.000435	CcSEcCtD
Aprepitant—Rash—Triamcinolone—multiple sclerosis	4.68e-05	0.000432	CcSEcCtD
Aprepitant—Dermatitis—Triamcinolone—multiple sclerosis	4.68e-05	0.000432	CcSEcCtD
Aprepitant—Anorexia—Methotrexate—multiple sclerosis	4.68e-05	0.000432	CcSEcCtD
Aprepitant—Rash—Methylprednisolone—multiple sclerosis	4.67e-05	0.000431	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—CNR1—multiple sclerosis	4.67e-05	0.000881	CbGpPWpGaD
Aprepitant—Dermatitis—Methylprednisolone—multiple sclerosis	4.67e-05	0.000431	CcSEcCtD
Aprepitant—Urticaria—Prednisone—multiple sclerosis	4.66e-05	0.00043	CcSEcCtD
Aprepitant—Headache—Triamcinolone—multiple sclerosis	4.65e-05	0.00043	CcSEcCtD
Aprepitant—Headache—Methylprednisolone—multiple sclerosis	4.64e-05	0.000429	CcSEcCtD
Aprepitant—Abdominal pain—Prednisone—multiple sclerosis	4.64e-05	0.000428	CcSEcCtD
Aprepitant—Body temperature increased—Prednisone—multiple sclerosis	4.64e-05	0.000428	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—CCR1—multiple sclerosis	4.64e-05	0.000876	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCL13—multiple sclerosis	4.64e-05	0.000876	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—TYK2—multiple sclerosis	4.63e-05	0.000875	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCL10—multiple sclerosis	4.63e-05	0.000874	CbGpPWpGaD
Aprepitant—Diarrhoea—Betamethasone—multiple sclerosis	4.61e-05	0.000426	CcSEcCtD
Aprepitant—Diarrhoea—Dexamethasone—multiple sclerosis	4.61e-05	0.000426	CcSEcCtD
Aprepitant—Hypotension—Methotrexate—multiple sclerosis	4.58e-05	0.000423	CcSEcCtD
Aprepitant—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.47e-05	0.000844	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	4.47e-05	0.000413	CcSEcCtD
Aprepitant—Dizziness—Dexamethasone—multiple sclerosis	4.46e-05	0.000411	CcSEcCtD
Aprepitant—Dizziness—Betamethasone—multiple sclerosis	4.46e-05	0.000411	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CD86—multiple sclerosis	4.45e-05	0.000839	CbGpPWpGaD
Aprepitant—Insomnia—Methotrexate—multiple sclerosis	4.44e-05	0.00041	CcSEcCtD
Aprepitant—Nausea—Triamcinolone—multiple sclerosis	4.41e-05	0.000407	CcSEcCtD
Aprepitant—Paraesthesia—Methotrexate—multiple sclerosis	4.4e-05	0.000407	CcSEcCtD
Aprepitant—Nausea—Methylprednisolone—multiple sclerosis	4.4e-05	0.000406	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CCL5—multiple sclerosis	4.38e-05	0.000826	CbGpPWpGaD
Aprepitant—Dyspnoea—Methotrexate—multiple sclerosis	4.37e-05	0.000404	CcSEcCtD
Aprepitant—Somnolence—Methotrexate—multiple sclerosis	4.36e-05	0.000403	CcSEcCtD
Aprepitant—Hypersensitivity—Prednisone—multiple sclerosis	4.32e-05	0.000399	CcSEcCtD
Aprepitant—Dyspepsia—Methotrexate—multiple sclerosis	4.32e-05	0.000399	CcSEcCtD
Aprepitant—Vomiting—Dexamethasone—multiple sclerosis	4.28e-05	0.000396	CcSEcCtD
Aprepitant—Vomiting—Betamethasone—multiple sclerosis	4.28e-05	0.000396	CcSEcCtD
Aprepitant—Decreased appetite—Methotrexate—multiple sclerosis	4.26e-05	0.000394	CcSEcCtD
Aprepitant—Rash—Dexamethasone—multiple sclerosis	4.25e-05	0.000392	CcSEcCtD
Aprepitant—Rash—Betamethasone—multiple sclerosis	4.25e-05	0.000392	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—IL2—multiple sclerosis	4.25e-05	0.000802	CbGpPWpGaD
Aprepitant—Dermatitis—Dexamethasone—multiple sclerosis	4.25e-05	0.000392	CcSEcCtD
Aprepitant—Dermatitis—Betamethasone—multiple sclerosis	4.25e-05	0.000392	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Methotrexate—multiple sclerosis	4.23e-05	0.000391	CcSEcCtD
Aprepitant—Fatigue—Methotrexate—multiple sclerosis	4.23e-05	0.00039	CcSEcCtD
Aprepitant—Headache—Dexamethasone—multiple sclerosis	4.22e-05	0.00039	CcSEcCtD
Aprepitant—Headache—Betamethasone—multiple sclerosis	4.22e-05	0.00039	CcSEcCtD
Aprepitant—Asthenia—Prednisone—multiple sclerosis	4.21e-05	0.000389	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—CXCL10—multiple sclerosis	4.2e-05	0.000794	CbGpPWpGaD
Aprepitant—Pain—Methotrexate—multiple sclerosis	4.19e-05	0.000387	CcSEcCtD
Aprepitant—Pruritus—Prednisone—multiple sclerosis	4.15e-05	0.000383	CcSEcCtD
Aprepitant—CYP3A7—Metabolism—SRM—multiple sclerosis	4.08e-05	0.00077	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SPP1—multiple sclerosis	4.05e-05	0.000765	CbGpPWpGaD
Aprepitant—Feeling abnormal—Methotrexate—multiple sclerosis	4.04e-05	0.000373	CcSEcCtD
Aprepitant—Diarrhoea—Prednisone—multiple sclerosis	4.02e-05	0.000371	CcSEcCtD
Aprepitant—Gastrointestinal pain—Methotrexate—multiple sclerosis	4.01e-05	0.00037	CcSEcCtD
Aprepitant—Nausea—Dexamethasone—multiple sclerosis	4e-05	0.00037	CcSEcCtD
Aprepitant—Nausea—Betamethasone—multiple sclerosis	4e-05	0.00037	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—CCL5—multiple sclerosis	3.98e-05	0.000752	CbGpPWpGaD
Aprepitant—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.98e-05	0.000751	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCR5—multiple sclerosis	3.94e-05	0.000745	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	3.93e-05	0.000742	CbGpPWpGaD
Aprepitant—Urticaria—Methotrexate—multiple sclerosis	3.9e-05	0.00036	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—IL2RA—multiple sclerosis	3.89e-05	0.000734	CbGpPWpGaD
Aprepitant—Dizziness—Prednisone—multiple sclerosis	3.88e-05	0.000358	CcSEcCtD
Aprepitant—Body temperature increased—Methotrexate—multiple sclerosis	3.88e-05	0.000358	CcSEcCtD
Aprepitant—Abdominal pain—Methotrexate—multiple sclerosis	3.88e-05	0.000358	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—IL2—multiple sclerosis	3.86e-05	0.000728	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	3.83e-05	0.000722	CbGpPWpGaD
Aprepitant—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.82e-05	0.000721	CbGpPWpGaD
Aprepitant—CYP3A7—Biological oxidations—POMC—multiple sclerosis	3.78e-05	0.000713	CbGpPWpGaD
Aprepitant—Vomiting—Prednisone—multiple sclerosis	3.73e-05	0.000344	CcSEcCtD
Aprepitant—Rash—Prednisone—multiple sclerosis	3.7e-05	0.000342	CcSEcCtD
Aprepitant—Dermatitis—Prednisone—multiple sclerosis	3.7e-05	0.000341	CcSEcCtD
Aprepitant—Headache—Prednisone—multiple sclerosis	3.68e-05	0.000339	CcSEcCtD
Aprepitant—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.62e-05	0.000684	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CCL5—multiple sclerosis	3.62e-05	0.000683	CbGpPWpGaD
Aprepitant—Hypersensitivity—Methotrexate—multiple sclerosis	3.61e-05	0.000334	CcSEcCtD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	3.6e-05	0.000681	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	3.6e-05	0.000681	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CCR5—multiple sclerosis	3.59e-05	0.000678	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—APOE—multiple sclerosis	3.59e-05	0.000677	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—IL2RA—multiple sclerosis	3.54e-05	0.000668	CbGpPWpGaD
Aprepitant—Asthenia—Methotrexate—multiple sclerosis	3.52e-05	0.000325	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	3.51e-05	0.000662	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	3.49e-05	0.00066	CbGpPWpGaD
Aprepitant—Nausea—Prednisone—multiple sclerosis	3.49e-05	0.000322	CcSEcCtD
Aprepitant—Pruritus—Methotrexate—multiple sclerosis	3.47e-05	0.00032	CcSEcCtD
Aprepitant—Diarrhoea—Methotrexate—multiple sclerosis	3.36e-05	0.00031	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—CCL3—multiple sclerosis	3.3e-05	0.000624	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	3.29e-05	0.000621	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	3.29e-05	0.000621	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CCR5—multiple sclerosis	3.26e-05	0.000615	CbGpPWpGaD
Aprepitant—Dizziness—Methotrexate—multiple sclerosis	3.24e-05	0.000299	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CD80—multiple sclerosis	3.24e-05	0.000612	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL2RA—multiple sclerosis	3.21e-05	0.000607	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTGER4—multiple sclerosis	3.18e-05	0.000601	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PGR—multiple sclerosis	3.13e-05	0.000591	CbGpPWpGaD
Aprepitant—Vomiting—Methotrexate—multiple sclerosis	3.12e-05	0.000288	CcSEcCtD
Aprepitant—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.1e-05	0.000585	CbGpPWpGaD
Aprepitant—Rash—Methotrexate—multiple sclerosis	3.09e-05	0.000285	CcSEcCtD
Aprepitant—Dermatitis—Methotrexate—multiple sclerosis	3.09e-05	0.000285	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—POMC—multiple sclerosis	3.08e-05	0.000582	CbGpPWpGaD
Aprepitant—Headache—Methotrexate—multiple sclerosis	3.07e-05	0.000284	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—CXCR3—multiple sclerosis	3.07e-05	0.00058	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CD28—multiple sclerosis	3.04e-05	0.000575	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCL2—multiple sclerosis	3.02e-05	0.000569	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCR2—multiple sclerosis	2.99e-05	0.000564	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—MAPK1—multiple sclerosis	2.95e-05	0.000557	CbGpPWpGaD
Aprepitant—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.95e-05	0.000557	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—SRM—multiple sclerosis	2.95e-05	0.000556	CbGpPWpGaD
Aprepitant—Nausea—Methotrexate—multiple sclerosis	2.91e-05	0.000269	CcSEcCtD
Aprepitant—CYP3A7—Metabolism—CYP27B1—multiple sclerosis	2.87e-05	0.000542	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP24A1—multiple sclerosis	2.87e-05	0.000542	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.81e-05	0.00053	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.81e-05	0.00053	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—POMC—multiple sclerosis	2.81e-05	0.00053	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CNR1—multiple sclerosis	2.76e-05	0.000521	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TYK2—multiple sclerosis	2.74e-05	0.000517	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	2.73e-05	0.000516	CbGpPWpGaD
Aprepitant—CYP3A5—Biological oxidations—POMC—multiple sclerosis	2.73e-05	0.000516	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	2.72e-05	0.000515	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	2.67e-05	0.000505	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GPC5—multiple sclerosis	2.63e-05	0.000496	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—POMC—multiple sclerosis	2.55e-05	0.000481	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	2.54e-05	0.00048	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	2.54e-05	0.00048	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CCL2—multiple sclerosis	2.49e-05	0.000471	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCL10—multiple sclerosis	2.48e-05	0.000469	CbGpPWpGaD
Aprepitant—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.39e-05	0.000451	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SRM—multiple sclerosis	2.28e-05	0.00043	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL2—multiple sclerosis	2.28e-05	0.00043	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—IL6—multiple sclerosis	2.27e-05	0.000428	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—TYK2—multiple sclerosis	2.26e-05	0.000427	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—RRM1—multiple sclerosis	2.18e-05	0.000411	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CD86—multiple sclerosis	2.17e-05	0.00041	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MMP9—multiple sclerosis	2.16e-05	0.000407	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCL5—multiple sclerosis	2.14e-05	0.000404	CbGpPWpGaD
Aprepitant—CYP2C19—Biological oxidations—POMC—multiple sclerosis	2.11e-05	0.000399	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SRM—multiple sclerosis	2.08e-05	0.000392	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	2.08e-05	0.000392	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	2.08e-05	0.000392	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—IL2—multiple sclerosis	2.07e-05	0.000392	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SPP1—multiple sclerosis	1.98e-05	0.000374	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCR5—multiple sclerosis	1.93e-05	0.000364	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—POMC—multiple sclerosis	1.93e-05	0.000364	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—STAT3—multiple sclerosis	1.92e-05	0.000362	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GPC5—multiple sclerosis	1.9e-05	0.000359	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL2RA—multiple sclerosis	1.9e-05	0.000358	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL2—multiple sclerosis	1.88e-05	0.000356	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MYC—multiple sclerosis	1.78e-05	0.000336	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TGFB1—multiple sclerosis	1.78e-05	0.000336	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SRM—multiple sclerosis	1.78e-05	0.000335	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—APOE—multiple sclerosis	1.75e-05	0.000331	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MAPK1—multiple sclerosis	1.74e-05	0.000329	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—POMC—multiple sclerosis	1.65e-05	0.000311	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	1.61e-05	0.000303	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	1.61e-05	0.000303	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CD80—multiple sclerosis	1.58e-05	0.000299	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—RRM1—multiple sclerosis	1.57e-05	0.000297	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.57e-05	0.000296	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—POMC—multiple sclerosis	1.5e-05	0.000284	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCL2—multiple sclerosis	1.47e-05	0.000278	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GPC5—multiple sclerosis	1.47e-05	0.000277	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	1.46e-05	0.000276	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	1.46e-05	0.000276	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—MAPK1—multiple sclerosis	1.44e-05	0.000272	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.43e-05	0.00027	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SRM—multiple sclerosis	1.37e-05	0.000259	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL6—multiple sclerosis	1.34e-05	0.000253	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.34e-05	0.000253	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TYK2—multiple sclerosis	1.34e-05	0.000252	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.27e-05	0.00024	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.25e-05	0.000236	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.25e-05	0.000236	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—BCHE—multiple sclerosis	1.25e-05	0.000236	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.22e-05	0.000231	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.22e-05	0.00023	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.14e-05	0.000216	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL2—multiple sclerosis	1.11e-05	0.00021	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.11e-05	0.000209	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL6—multiple sclerosis	1.11e-05	0.000209	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MMP9—multiple sclerosis	1.05e-05	0.000199	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	9.65e-06	0.000182	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	9.65e-06	0.000182	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—RRM1—multiple sclerosis	9.48e-06	0.000179	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	9.44e-06	0.000178	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—STAT3—multiple sclerosis	9.36e-06	0.000177	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—BCHE—multiple sclerosis	9.04e-06	0.000171	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GPC5—multiple sclerosis	8.83e-06	0.000167	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MYC—multiple sclerosis	8.7e-06	0.000164	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TGFB1—multiple sclerosis	8.68e-06	0.000164	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.61e-06	0.000162	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MAPK1—multiple sclerosis	8.51e-06	0.000161	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.11e-06	0.000153	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—APOE—multiple sclerosis	7.52e-06	0.000142	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.39e-06	0.00014	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	7.39e-06	0.00014	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.35e-06	0.000139	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—RRM1—multiple sclerosis	7.32e-06	0.000138	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—BCHE—multiple sclerosis	6.99e-06	0.000132	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.74e-06	0.000127	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL6—multiple sclerosis	6.54e-06	0.000123	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—POMC—multiple sclerosis	6.46e-06	0.000122	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—BCHE—multiple sclerosis	6.37e-06	0.00012	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.32e-06	0.000119	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ALB—multiple sclerosis	5.89e-06	0.000111	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.76e-06	0.000109	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—BCHE—multiple sclerosis	5.44e-06	0.000103	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—APOE—multiple sclerosis	5.44e-06	0.000103	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—POMC—multiple sclerosis	4.67e-06	8.82e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ALB—multiple sclerosis	4.26e-06	8.04e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—APOE—multiple sclerosis	4.2e-06	7.94e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—BCHE—multiple sclerosis	4.2e-06	7.93e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—APOE—multiple sclerosis	3.83e-06	7.24e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—POMC—multiple sclerosis	3.61e-06	6.82e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—POMC—multiple sclerosis	3.29e-06	6.22e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALB—multiple sclerosis	3.29e-06	6.22e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—APOE—multiple sclerosis	3.28e-06	6.18e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALB—multiple sclerosis	3e-06	5.67e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—POMC—multiple sclerosis	2.81e-06	5.31e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALB—multiple sclerosis	2.57e-06	4.84e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—APOE—multiple sclerosis	2.53e-06	4.77e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—POMC—multiple sclerosis	2.17e-06	4.1e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALB—multiple sclerosis	1.98e-06	3.74e-05	CbGpPWpGaD
